Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The safety and efficacy of CC-95251 in combination with rituximab for R/R NHL

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the safety and efficacy of CC-95251, a novel monoclonal antibody targeting SIRPα, for the treatment of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Dr Strati first explains the advantages of targeting SIRPα, and then goes on to discuss the interim results of a trial evaluating the safety and efficacy of this agent in combination with rituximab for patients with R/R NHL (NCT03783403). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Advisory Board/Consultancy: Roche Genentech, Hutchinson MediPharma, ADC Therapeutic, TG Therapeutics, Incyte Morphosis, Kite Gilead
Research Support: Astrazeneca Acerta, ADC Therapeutics, Sobi Pharmaceutics, ALX Oncology